New research presented at ASH 2025 shows that Yescarta® continues to deliver reliable results for patients battling relapsed or refractory large B-cell lymphoma—even for those too sick to receive high-dose chemotherapy and a stem cell transplant.
The findings combine long-term data from two clinical trials: the four-year ZUMA-7 study and the two-year ALYCANTE study. Together, they show that Yescarta’s benefits remain consistent across different patient groups, including older adults and those with additional health challenges.
What the numbers show after two years:
• Nearly 65% of patients in the combined analysis were still alive.
• About 45% had no disease progression or major complications (EFS).
• Almost 47% were living without their cancer worsening (PFS).
Patients also experienced strong early responses—more than half showed almost no detectable disease at three months.
Safety results were similar between studies, and side effects were generally manageable.
Importantly, patients’ quality of life steadily improved within months of treatment and continued to do so over the long term.
Experts say the results further support Yescarta as a second-line standard of care and highlight the promise of CAR T-cell therapy for patients who previously had few effective options.